Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma

J Mark Fitzgerald (1) , Eugene R. Bleecker (2) , Arnaud Bourdin (3, 4) , William Busse (5) , Gary Ferguson (6) , Laura Brooks , Peter Barker , Ubaldo Martin

1 The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, BC
2 Center for Genomics and Personalized Medicine
3 PhyMedExp - Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046]
4 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
5 Department of Medicine
6 Pulmonary Research Institute of Southeast Michigan,

Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody. Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year for patients with severe, uncontrolled eosinophilic asthma.

Mots clés: asthma; benralizumab; clinical features; eosinophilic inflammation; interleukin-5 receptor; safety

Domaines: Sciences du Vivant [q-bio]

J Mark Fitzgerald, Eugene R. Bleecker, Arnaud Bourdin, William Busse, Gary Ferguson, et al..

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma

. Journal of Asthma and Allergy, 2019, Volume 12, pp.401-413. ⟨10.2147/JAA.S227170⟩. ⟨hal-02419280⟩